Chapter 26 — Case Study 1: Aspirin's Mode of Action — Acyl Transfer to COX

"Aspirin is the most-prescribed drug in human history. Its mechanism is a single nucleophilic acyl substitution onto a serine residue." — modern medicinal chemistry text, paraphrased

Aspirin (acetylsalicylic acid) was first synthesized in 1897 by Felix Hoffmann at Bayer. Today it is taken by more than 100 million people daily, primarily for cardiovascular disease prevention. Its mechanism — and the chemical reason for its uniqueness — is a textbook example of nucleophilic acyl substitution.

This case study traces the chemistry from synthesis to mechanism on the target enzyme.

Aspirin's structure: two carbonyls in one molecule

Aspirin contains two carbonyl groups: 1. Carboxylic acid (-COOH) at C1 of the salicylate ring. 2. Ester (-OC(=O)CH₃) at C2 — an acetyl group attached to the phenol-O of salicylate.

The structure is: $\text{2-(acetyloxy)benzoic acid} = $ ortho-acetyloxy-substituted benzoic acid.

The two carbonyls have different reactivities: - The COOH is moderately reactive (Section 26.7), but it is not the active group for the drug action. - The ester is the active acetyl source. It is moderately reactive — fast enough to react with COX's serine in the body, slow enough to circulate in blood without spontaneous hydrolysis.

This balance — fast enough to react where wanted, slow enough to deliver — is by design. Salicylic acid alone (no acetyl group) is much harsher on the stomach lining. Aspirin's acetylation acts as both a slow-release modifier and the active group for COX inhibition.

How aspirin is synthesized (Section 26.4 mechanism)

Industrial aspirin synthesis: 1. Salicylic acid (made from phenol + CO₂ + base, Kolbe-Schmitt reaction, Ch 21) is the starting material. 2. Mix with acetic anhydride plus a small amount of sulfuric acid (catalyst). 3. The phenol OH (the -OH ortho to the COOH) is the nucleophile. 4. Phenol-OH attacks the protonated C=O of acetic anhydride. 5. Tetrahedral intermediate forms. 6. Acetate leaves (as the conjugate base of acetic acid). 7. Product: aspirin + acetic acid.

Why the phenol OH and not the COOH? Because the phenol is protonated less easily than the COOH (lower pKa of the phenolate, ~10) and because the phenol O is a better nucleophile than the COOH-OH (which is involved in a hydrogen-bond network with the C=O). At low pH (sulfuric acid catalyst), the COOH stays protonated and is less reactive; the phenol-OH is the only nucleophile available.

Industrial scale: ~50,000 tons of aspirin per year. Crystallized from water; sold in tablets at 81 mg (low-dose) to 325 mg (regular).

Aspirin's mechanism on COX

In the body, aspirin reaches cyclooxygenase enzymes (COX-1 and COX-2). These enzymes convert arachidonic acid (a 20-carbon polyunsaturated fatty acid) to prostaglandins, which mediate inflammation, pain, and platelet activation.

Aspirin's mechanism: 1. Aspirin binds to COX's substrate channel (the same pocket that binds arachidonic acid). 2. Within the channel, aspirin's ester C=O comes within reaction distance of serine 530 (a hydroxyl-bearing residue at the active site). 3. The serine OH attacks the ester C=O carbon of aspirin (nucleophilic acyl substitution). 4. Tetrahedral intermediate forms. 5. Salicylate leaves as the leaving group. 6. The result: acetyl-Ser530 + free salicylate.

Mechanism Map: Aspirin + COX-Ser-OH. 1. Ser-OH lone pair attacks aspirin's acetyl C=O. Tetrahedral intermediate (with -O⁻, -OAr (the salicylate-O), -CH₃, -OSer on C). 2. Salicylate-O leaves (it is a better leaving group than the new C-OSer bond would be). 3. The C=O is restored on the now-acetylated serine. 4. Product: COX-Ser-O-CO-CH₃ (acetylated COX serine) + free salicylate (the deprotonated form of salicylic acid).

The acetylation inactivates the enzyme. Arachidonic acid can no longer enter the active site (the channel is now plugged by the acetyl group on Ser530). The cell must synthesize new COX (which takes hours) before prostaglandin production resumes.

This is why aspirin's effect on platelet COX (specifically COX-1 in platelets) lasts ~10 days: platelets are anucleate cells that cannot synthesize new protein. Once their COX is acetylated, it stays acetylated for the platelet's lifetime.

Why the irreversibility matters clinically

Most drugs work by reversible binding: the drug binds, the enzyme is inhibited; the drug unbinds, the enzyme is freed. The pharmacokinetics of such drugs require that the drug be at a sufficient concentration to keep the enzyme inhibited.

Aspirin is different. Once it acetylates COX, the modification is permanent. So even after aspirin is metabolized and cleared from the body (half-life ~3 hours), the COX remains inactivated until new COX is synthesized.

This is why low-dose aspirin (81 mg/day) is so effective for cardiovascular protection: each daily dose acetylates a fraction of the platelet COX. Since platelet turnover is ~10 days, daily low-dose aspirin keeps a steady fraction of platelets COX-inactivated. The platelets cannot aggregate efficiently (because they cannot make thromboxane A₂, a potent platelet activator), and the risk of arterial clots is reduced.

COX-1 vs. COX-2 selectivity (and the next-generation drugs)

There are two main isoforms of COX: - COX-1: constitutively expressed; in platelets, stomach, kidneys. Produces protective prostaglandins (gastric protection, platelet aggregation, kidney function). - COX-2: induced by inflammation; in inflamed tissues. Produces inflammatory prostaglandins.

Aspirin inhibits both COX-1 and COX-2 (it is non-selective). The COX-1 inhibition is responsible for some side effects (GI bleeding, kidney issues) but also for the cardio-protective effect (platelet inhibition). The COX-2 inhibition is responsible for the anti-inflammatory effect.

In the 1990s-2000s, COX-2-selective inhibitors (rofecoxib/Vioxx, celecoxib/Celebrex) were developed to reduce GI side effects. They work by reversible binding rather than acyl transfer — they're a fundamentally different chemical class. Vioxx was withdrawn in 2004 due to cardiovascular side effects (thought to be due to disrupting the COX-1/COX-2 balance in the cardiovascular system). Celecoxib remains in use.

The lesson: aspirin's irreversible acyl-transfer mechanism is unique among NSAIDs, and is the basis of its cardiovascular benefit. It is not just an alternative to ibuprofen or naproxen — it is mechanistically distinct.

Other irreversible inhibitors via acyl transfer

Aspirin is the most famous, but it is not the only drug whose mechanism is irreversible acyl transfer to a serine. Examples include:

• Penicillin and other β-lactam antibiotics: penicillin's strained 4-membered amide is opened by a serine in bacterial transpeptidase (PBP) — exactly the same acyl-transfer mechanism.
• Trastuzumab (Herceptin) and other antibody-drug conjugates: some payloads attached to antibodies are designed to acylate target tyrosines or lysines.
• Suicide enzyme inhibitors in general.

Aspirin's broader pharmacology

Beyond its COX inhibition, aspirin has additional effects: - Acetylates other serines and lysines on various proteins (including hemoglobin), giving a measurable "acetylation profile" that some studies use as a biomarker. - The salicylate metabolite has its own anti-inflammatory effects, possibly through different mechanisms (NF-κB inhibition, etc.). - At higher doses (4 g/day or more), aspirin can have additional effects on platelet function, prostacyclin balance, and immune signaling.

Forward connections

Chapter 33 returns to enzyme mechanisms, including the serine protease catalytic triad (a chemistry related to aspirin's mechanism — also a serine attacking a carbonyl). Chapter 34 covers fatty acid biology, including the prostaglandins and thromboxanes that aspirin disrupts.

Take-home

• Aspirin is acetylsalicylic acid: a salicylate with an acetyl ester at the phenol position.
• Synthesis: salicylic acid + acetic anhydride + acid catalyst → aspirin + acetic acid (nucleophilic acyl substitution).
• Mechanism in the body: aspirin's ester acetyl group is transferred to COX's Ser530 by nucleophilic acyl substitution. Salicylate is the leaving group.
• The COX is permanently modified; new COX must be synthesized for prostaglandin production to resume.
• This irreversibility makes aspirin uniquely useful for low-dose, long-term cardiovascular protection — and it is why aspirin's mechanism is mechanistically distinct from reversible NSAIDs (like ibuprofen).
• Aspirin is a textbook example of nucleophilic acyl substitution applied to medicine: a single mechanism, a profound clinical effect, used by ~100 million people daily.